Business Promotion Department ,Senior Manager

• Mar 2014 - Present

Business planning Department Precision Medicine Business OperationPrecision Medicine Business Unit Business planning Department Precision Medicine Business OperationPrecision Medicine Business Unit

戦略アドバイザー

• Mar 2014 - Present

Senior Consultant for Business Development

• May 2013 - Present

CEO

• Jun 2013 - Present

●Marketing consaltation. ●Regulatory Affairs Professionals for pharmaceutical, Medical device, In Vitro Daignostic ●Marketing consaltation. ●Regulatory Affairs Professionals for pharmaceutical, Medical device, In Vitro Daignostic

Marketing Advisor

• Nov 2010 - Present

Medical Consulting Specialist

• Jul 2019 - Present

Business Consultant

• Mar 2015 - Present

Consulting Specialist

• Apr 2019 - Present

Senior Consultant for Medical

• Jun 2021 - Present

Senior Consultant

• Oct 2017 - Present

Senior Consultant

• Jun 2021 - Present

Senior Consultant

• May 2021 - Present

Consaltant

• Oct 2018 - Present

Consultant

• Mar 2018 - Present

Consultant

• Jun 2017 - Present

医療コンサルタント

• Dec 2017 - Present

Senior Consultant

• Sep 2017 - Present

Consulting Specialist, Medical Consulting Specialis

• Jan 2014 - Present

Chief Marketing Officer

• Jun 2007 - Mar 2013

The microfluidic cell sorter system using new technology, which develped to life sciense market. The microfluidic cell sorter system using new technology, which develped to life sciense market.

Chife Marketing Officer; Bisness development Director

• Jun 2007 - Mar 2013

We are developing Microfluidic flow cytometer & Cell Sorter since 2006.Now. the final product is completed, then we release this product at Jun 2009 in Japanese Market. We are developing Microfluidic flow cytometer & Cell Sorter since 2006.Now. the final product is completed, then we release this product at Jun 2009 in Japanese Market.

Director Of Marketing And Business Development

• Nov 1994 - Mar 2007

1.The business model's decision (1).Construction of the business model who analyzes market trend, and is new (2).Domestic sale strategy decision and execution (3).Plan of business scheme and marketing strategy2.Long-term plan making (1).Project and plan of brand growth strategy(Short ＆A mid/long term) (2).Mid/long-term goal setting that takes a sight to marketing, design, and operation in business process (3).Management of global brand-name goods (4).TPP(Target Product Profile) is examined. 3.Development of product that exists in Japanese market trend4.Achievement analysis/profit management/marketing analysis5.Construction of marketing plan and marketing process6.Each area and the section, and an accurate, efficiency of public relations and the assumed process, and effective monitor and management, etc.7.Channel partner's management8.Excellent relation making with association society9. Public relations business with the Ministry of Health, Labour and Welfare10. Communications with headquarters11. The staff is coached and their career plans are promoted. 12. Business tie-up, examination of M&A, and promotion

R&D Project Manager

• Nov 1987 - Oct 1994

AchievementThe following medicine was completed to final product. (1). Anti-cancer medicine: 5 products (2). Injection : 3 product (Epirubcin, Idarubicin and Cisplacin)(3). Tablet 1 product (Hisron –H)(4) encapsulated formulation 1 product (Torterodin,)Duties contents1. Research of physics and chemistry properties2. Screening test3. Non-clinical study< For GLP >< For GCP >Phase I study to Phase III study 5. Approval and permission application(1). Making of material concerning application for approval for the Ministry of Health and Welfare. (2) Decision of answer book concerning answer instruction matter. (3). Matter concerning right or wrong of introduction of overseas data.6. Manufacturing approval< For GMP >Validation. The quality information in the medicine manufacturers is evaluated and analyzed. 7. Standard prices of medicines8. Post marketing surveillance (PMS)< For GPMSP >(1). Investigation report concerning side effect like thrombosis by medicine made of High dose progesterone administering in breast cancer patient etc. and side effect measures conferences with the Ministry of Health and Welfare.(2). Early postmarketing phase vigilance (six months from sales beginning) and use result investigations (effectiveness and safety)(3). Special investigation (six months after Hageme to infant, senior citizen, and pregnant woman,etc. ..investigation and sales.. ..unsealing..)(4). Re-examination of drug, revaluation, and side effect and infectious disease report system